What patients pay — the three pricing tiers

The published guide costs from London Cartilage Clinic at 66 Harley Street — the only UK clinic to have released a structured pricing schedule for ChondroFiller — set out three tiers based on the volume of product required:

• One box (2.3 mL): £3,000
• Two boxes (4.6 mL): £5,500
• Three boxes (6.9 mL): £8,000

For the most extensive multi-compartment presentations, the total may reach £8,000–£9,800.

Every tier is fully bundled. The guide cost covers the initial clinical consultation, real-time ultrasound guidance, the ChondroFiller implant, intravenous antibiotic prophylaxis administered on the day, the injection procedure, and a six-week follow-up appointment. Patients are not billed separately for imaging, the post-procedure review, or any other element of the standard pathway.

The appropriate tier is determined at clinical assessment — not chosen in advance by the patient. Defect size and joint condition, established through imaging, drive the decision. Most focal cartilage lesions require a single box, which places the majority of patients at the £3,000 tier; the two- and three-box courses are reserved for larger or more complex presentations.

Because no other UK provider has published a comparable pricing schedule, the London Cartilage Clinic figures serve as the de facto national reference for ChondroFiller guide costs.

Why ChondroFiller costs more than a standard joint injection

The gap between a ChondroFiller appointment and a standard hyaluronic acid or corticosteroid injection is rooted in regulatory classification, not clinic pricing policy.

ChondroFiller (Liquid Cartilage™) is a CE-marked Class III medical device — the highest-risk category under European and UK medical device regulation — manufactured by Meidrix Biomedicals GmbH in Germany and supplied under prescription. Class III status is reserved for devices that perform an active biological role inside the body. In ChondroFiller's case, the collagen scaffold gels in situ within the defect and initiates acellular matrix-induced chondrogenesis — in plain terms, it recruits the patient's own repair cells from the surrounding synovium and subchondral bone rather than simply lubricating the joint.

Hyaluronic acid and corticosteroid formulations carry no equivalent classification. Both are established, simpler preparations used for symptom relief rather than tissue-level repair, and their manufacturing pathway does not attract the same regulatory overhead.

The higher cost of ChondroFiller reflects what it costs to produce, license, and import a Class III biological scaffold to prescription standard. That distinction in regulatory burden, manufacturing complexity, and mechanism of action is what separates the price point from a routine injection appointment.

CCSD procedure codes — W3111 and when W8500 applies

Two CCSD procedure codes appear on UK private insurer fee schedules in connection with ChondroFiller: W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). They are not interchangeable, and understanding the difference matters when preparing a pre-authorisation request.

W3111 is the code to quote. It is the principal billing code covering the ChondroFiller implant and the procedure itself. For the standard pathway at London Cartilage Clinic — ultrasound-guided outpatient injection — W3111 is the only code applicable. Patients submitting a pre-authorisation request to their insurer should reference W3111 as the primary code.

W8500 covers a different delivery route entirely. Arthroscopy — a surgical procedure performed in a theatre under anaesthetic — represents one way ChondroFiller can be implanted, but it is not the outpatient injection pathway. W8500 exists on insurer fee schedules alongside W3111 precisely because some providers use a theatre-based route; at London Cartilage Clinic, the treatment is an image-guided clinic appointment, not a surgical admission. Quoting W8500 in a pre-authorisation request for the outpatient pathway would misrepresent the procedure to the insurer.

If an insurer asks for clarification, patients can confirm that treatment is being delivered as an ultrasound-guided outpatient injection — and that W8500 therefore does not apply.

Private insurance — realistic expectations for coverage

Private medical insurance rarely makes ChondroFiller straightforward to claim. No major UK insurer lists it as a standard policy benefit; coverage is assessed case by case, at the insurer's discretion, on the basis of the individual policy and the clinical justification submitted.

That said, written pre-authorisation has been granted — most commonly reported through Bupa, Aviva, and WPA, according to clinical practice experience from October 2025. These approvals are neither routine nor guaranteed, and the same insurer may reach different decisions for different patients depending on their policy tier and presenting diagnosis.

The procedural rule is firm: written pre-authorisation must be obtained before booking treatment. Verbal telephone approvals and retrospective claims after the appointment are not accepted. If authorisation is not confirmed in writing beforehand, the full cost falls to the patient regardless of what was discussed with the insurer over the phone.

Partial coverage is also possible. Some insurers may agree to fund the initial consultation or the six-week follow-up while excluding the implant cost itself — which represents the majority of the guide fee. Patients should ask their insurer specifically what components of the procedure are covered, not simply whether the treatment is covered in principle.

ChondroFiller sits entirely outside NHS provision; there is no referral route through the health service.

Combination protocols and the upper end of the price range

The £3,000–£8,000 scaffold-only range does not represent every quote a patient with more complex joint disease will receive. For moderate-to-severe osteoarthritis presentations, London Cartilage Clinic offers combination protocols that extend the cost spectrum considerably beyond the standard tiers.

The first step up is ChondroFiller combined with Arthrosamid, a polyacrylamide hydrogel, at approximately £6,000. ChondroFiller in this pairing is the regenerative scaffold component — it recruits the patient's own progenitor cells through acellular matrix-induced chondrogenesis. Arthrosamid is non-regenerative: it provides mechanical cushioning within the joint rather than promoting tissue repair. The two products work through entirely different mechanisms and should not be treated as two versions of the same injectable.

Further along the spectrum, the CFI++ protocol — combining ChondroFiller, mesenchymal stem cells, and Arthrosamid — starts from approximately £10,500. The Tri-Active Therapy, which packages the same three elements, is priced at approximately £11,000. Both are reserved for more extensive or multi-compartment osteoarthritis where a single-scaffold approach would be insufficient; they are not offered to patients with straightforward focal defects.

None of these protocols is offered as a standard upgrade. The treating clinician determines which combination, if any, is appropriate based on imaging, lesion severity, and overall joint condition — patients do not select the protocol themselves.

What happens at assessment — and how to take the next step

Cost transparency in this pathway runs through the clinical assessment, not before it. The tier structure sets the range, but which tier applies to a specific patient depends on findings that can only be confirmed in person: the size and depth of the cartilage lesion, the condition of the surrounding joint, and whether the defect is focal or involves multiple compartments. Those variables cannot be read from a website.

For patients presenting with a focal defect, most assessments confirm a single-box approach at £3,000. Crucially, the appointment produces a specific recommended protocol and a confirmed guide cost before any treatment decision is made — patients are not asked to commit before understanding what the procedure involves for their particular joint.

At London Cartilage Clinic, that assessment is conducted by Professor Paul Y. F. Lee, whose practice centres on cartilage-preservation and regenerative joint pathways. Initial consultations can be arranged through londoncartilage.com.